Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00072163 · ClinicalTrials.gov registry record · Phase 2
Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma
A Phase 2 study of Recurrent Melanoma and Stage IV Melanoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT00072163 is a Phase 2 study of Recurrent Melanoma and Stage IV Melanoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 50 participants, below the 171-participant average among 23 other Recurrent Melanoma trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00072163, a Phase 2 study of Recurrent Melanoma and Stage IV Melanoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial is studying how well giving temozolomide together with thalidomide works in treating patients with brain metastases secondary to melanoma. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Combining temozolomide with thalidomide may kill more tumor cells
Conditions Studied
Interventions
- DRUG temozolomide
- DRUG thalidomide
Study Locations (1)
Illinois
- Cancer and Leukemia Group B - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2003-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00072163
The ClinicalTrials.gov registry entry for NCT00072163 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 171-participant average among 23 other Recurrent Melanoma trials with a reported enrollment target (71% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Recurrent Melanoma appearing as the primary indexed condition, and to 2 interventions - of which temozolomide is the first listed.
NCT00072163 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT00072163 about?
NCT00072163 is a clinical study titled "Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma". This phase II trial is studying how well giving temozolomide together with thalidomide works in treating patients with brain metastases secondary to melanoma. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop tumor cells from dividing so they stop growing or die. Thali...
What is the current status of trial NCT00072163?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2003-10.
What conditions does trial NCT00072163 study?
This clinical trial studies the following conditions: Recurrent Melanoma, Stage IV Melanoma, Tumors Metastatic to Brain.
What interventions are being tested in trial NCT00072163?
The interventions under investigation include: temozolomide (DRUG), thalidomide (DRUG).
Who is sponsoring clinical trial NCT00072163?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00072163 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dinaciclib in Treating Patients With Stage IV Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
ACTIVE NOT RECRUITING · Phase 2
-
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
ACTIVE NOT RECRUITING · Phase 2
-
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
COMPLETED · Phase 2
-
Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.